The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 in the Immune System, 2012Does Peripheral Immune Challenge Exacerbate LRRK2-Induced Neuronal Pathology?
Objective/Rationale:
Neuro-immune interactions may have etiological roles in the development of several neurodegenerative disorders. LRRK2 is a cell signaling protein and when mutated, is... -
Therapeutic Pipeline Program, 2013Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson’s Disease
Objective/Rationale:
Erythropoietin (EPO) receptor is present throughout the body and plays a role in both red blood cell production and tissue protection. STATegics has discovered small... -
Aligning Science Across Parkinson's, 2021Understanding and Manipulating Cellular and Circuit-level Vulnerability to Neurodegeneration in Parkinson’s Disease
Study Rationale:
Many people with Parkinson’s disease develop untreatable cognitive symptoms, including problems with attention, decision-making, and dementia at late stages of the disease, due to... -
Edmond J. Safra Movement Disorders Research Career Development Award, 2024Towards a Better Understanding of Treatment-refractory Gait Issues in Parkinson’s Disease
Study Rationale: Freezing of gait (FOG) is a sudden arrest of gait despite the intention to continue walking, often while a person is turning, walking in a confined space or is in a situation that...
-
Circuits & Cellular Targets for PD’s Symptoms, 2025Role of B2*-Nicotinic Receptors in Parkinson’s Disease Related Circuits and Symptoms
Study Rationale: One pathological hallmark of Parkinson’s disease (PD) is the degeneration of dopamine neurons innervating the striatum. Dopamine loss is associated with several adaptive changes in...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025SUPPLEMENT: IRL757 for the Treatment of Apathy in Parkinson's Disease
Study Rationale: People with PD frequently develop a loss of motivation and initiative. This phenomenon is called apathy and can be a very burdensome symptom of PD, affecting not only the patient but...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.